Indo-Bangla Pharmaceuticals Limited

DSE:IBP Stock Report

Market Cap: ৳1.6b

Indo-Bangla Pharmaceuticals Valuation

Is IBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IBP (BDT13.7) is trading above our estimate of fair value (BDT7.77)

Significantly Below Fair Value: IBP is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IBP?

Other financial metrics that can be useful for relative valuation.

IBP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.6x
Enterprise Value/EBITDA45.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IBP's PS Ratio compare to its peers?

The above table shows the PS ratio for IBP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
SILCOPHL Silco Pharmaceuticals
SILVAPHL Silva Pharmaceuticals
CENTRALPHL Central Pharmaceuticals
AMBEEPHA Ambee Pharmaceuticals
IBP Indo-Bangla Pharmaceuticals

Price-To-Sales vs Peers: IBP is good value based on its Price-To-Sales Ratio (7.5x) compared to the peer average (9.4x).

Price to Earnings Ratio vs Industry

How does IBP's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.5%
No more companies

Price-To-Sales vs Industry: IBP is expensive based on its Price-To-Sales Ratio (7.5x) compared to the Asian Pharmaceuticals industry average (2.4x).

Price to Sales Ratio vs Fair Ratio

What is IBP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IBP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IBP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.